Altimmune (ALT) announced publication in The Lancet of 24-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback